Melanoma Drugs Market Overview
Melanoma Drugs Market Size is estimated to reach $14.3 billion by 2027 and it is poised to grow at a CAGR of 7.5% over the forecast period of 2022-2027. Melanoma is a disorder or a form of cancer where the cell producing the skin color becomes cancerousc and the melanocytes start multiplying at an uncontrollable pace. Nearly 70-80% of melanoma arises on normal-looking skin, while only 20-30% of melanomas are found in the existing moles. The skin cancer market is divided into three types, of which the non-melanoma skin cancer market which includes basal cell carcinoma and squamous cell carcinoma has a higher prevalence than melanoma. The changing stature of ozone radiation and higher exposure to the unprotected sun are some of the critical reasons cited by the U.S. drug discovery magazine for increasing adolescent melanoma cancer cases. Owing to pharmaceutical advancements and an increasing patient pool, the melanoma drug industry will offer lucrative opportunities in the forecast period of 2022-2027.
Melanoma Drugs Market Report Coverage
The report: “Melanoma Drugs Market Forecast (2022-2027)" by IndustryARC covers an in-depth analysis of the following segments in the Melanoma Drugs Market.
by Disease Type- Superficial Spreading Melanoma,
Lentigo Maligna, Acral Lentiginous Melanoma and Nodular Melanoma.
by Drug Types – Chemotherapy, Immunotherapy and Targeted Therapy.
by Application- Hospitals, Outpatient Oncologist Clinics and Others.
by Geography: North America (the U.S., Canada and Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia and the Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia and New Zealand and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and Rest of the World (the Middle East and Africa).
- Geographically, North America dominated the market in 2021, primarily owing to a strong melanoma drugs market in the U.S. Further, the drug review policies in the U.S. along with the drug discovery and drug review process allow the market to grow. Moreover, Europe and North American region will offer lucrative opportunities owing to an increased incidence of melanoma in the population.
- The growing susceptible population subjugated by increasing prevalence across the age-groups act as a major driver for the market. However, the high-treatment cost associated with melanoma drugs impedes the market growth.
- A detailed analysis of the strengths, weaknesses, opportunities and threats will be provided in the Melanoma Drugs Market Report.
Melanoma Drugs Market- Market Share (%) by region, 2021.
For More Details on This Report - Request for Sample
Melanoma Drugs Market - by Disease Type
Melanoma Drugs Market based on disease type can be further segmented into Superficial Spreading Melanoma, Lentigo Maligna, Acral Lentiginous Melanoma and Nodular Melanoma. Superficial Spreading Melanoma held a dominant market share in the year 2021. The following form is the most common type of melanoma cancer, with a heightened incidence across the globe. It can arise in an existing mole or appear as a new lesion. However, Lentigo Maligna is estimated to be the fastest-growing, with a CAGR of 8.5% over the forecast period of 2022-2027. The following form of melanoma often develops in older people and becomes invasive or spreads beyond the original site. As per WHO, an estimated 402 million people or 28% of the Chinese population will be over the age of 60, supporting the melanoma drug industry in China.
Melanoma Drugs Market - by Drug Types
Melanoma Drugs Market based on drug types can be further segmented into Chemotherapy, Immunotherapy and Targeted Therapy. Immunotherapy held a dominant market share in the year 2021. The following shift in ranking replaces Chemotherapy, which no longer provides an effective remedy for the following cancer type. Pioneering breakthroughs in immunotherapy — the use of medicines to stimulate a patient’s immune system to destroy cancer cells - have led to significant progress in treating patients with advanced melanoma. However, Targeted Therapy is estimated to be the fastest-growing, with a CAGR of 8.9% over the forecast period of 2022-2027. As per various U.S. Drug Discovery magazines, targeted therapies will allow a personalized medicine approach with minimal damage to healthy cells. The following will act as a boon to countries such as Australia, which has a prevalence of 1 Australian diagnosed every 30 minutes, with extremely high death rates.
Melanoma Drugs Market - by Geography
Melanoma Drugs Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. The melanoma drugs market in North America held a dominant market share of 38% in the year 2021. It is owing to its high prevalence in the U.S. and Canada, with potentially high treatment costs and equipped medical awareness campaigns and diagnostic market. Moreover, Europe is estimated to offer lucrative growth opportunities in the forecast period owing to the growing geriatric population and the overall climate change superposition. As per NCBI, nearly 20,000 lives are lost in the EU owing to melanoma each year.
Melanoma Drugs Market Drivers
The Increasing Prevalence of Melanoma Cancer has Provided the Market with the Necessary Impetus
The number of cases of melanoma is on a significant increase, as per Skin Cancer. Org, an estimated 197,700 cases of melanoma will be diagnosed within the U.S. by 2022, which has propelled the melanoma drugs market in the U.S. Of the diagnosis, nearly 98,000 cases will be in-situ (non-invasive), confined to the epidermis (the top layer of the skin) and nearly 1,00,000 cases will be invasive, those which have penetrated skin’s second layer. Moreover, various drug review articles published in 2021 have highlighted critical changes in the overall drug review process, which in turn has proliferated the market.
The Growing Susceptible Geriatric Population Coupled with Rising Incidence in Younger Adults has Provided the Needed Push to Market Growth
Melanoma has often been considered a condition for older people. As per AIM AT MELANOMA Foundation, about 50% of melanomas within the countries occur in people above the age of 50, with a median age risk of 59. The geriatric population share in the countries like the U.S. is bound to increase from 11.6% to 16.7% in the coming decades as per CDC, which will support the market growth and claim. Incidentally, the incidence of melanoma is excruciatingly growing in young adults. As per WHO, melanoma is the third most prevalent cancer in men and women aged 15-29. Melanoma Drugs Market in North America is pushed by the incidence of nearly 400 cases of the following cancer being developed in patients within 20 years or younger.
Melanoma Drugs Market Challenges
Higher Cost Borne by Patients for Drugs and Other Treatment Clauses Impedes the Market Growth
One of the critical restraining factors for the market growth of melanoma drugs is the cost associated with the drugs and the overall treatment. A single cycle of therapy alone can cost a fortune and there are multiple cycles of chemotherapy, medications, test and surgeries required to treat melanoma skin cancer which is not affordable to many people across the world. Furthermore, the cost borne by the government continues to rise, which involuntarily will increase the pressure on insurance providers and premium prices. For example, CDC estimates that the annual cost of treating melanoma will touch $1.6 billion by 2030 and the cost would have been the fastest-growing among all forms of cancer in the U.S.
Melanoma Drugs Industry Outlook
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Melanoma Drugs Industry. The top 10 companies in the Melanoma Drugs Industry market are:
1. Takeda Pharma
2. F. Hoffmann-La Roche AG
3. Bristol Myers Squib Company
4. Novartis AG
5. Pfizer Inc.
6. Sanofi S.A.
7. Janssen Biotech
8. Glaxo Smith Kline
9. Amgen Inc
10. Pierre Fabre Group
- In September 2022, Researchers from the Netherlands found a new cell-based therapy for melanoma, which in turn has proven to be more effective than existing treatments. TIL-Therapy harvests the patient’s immune cell- amplified to produce billions of cells- and then pushed it back into the patient’s bloodstream, killing cancer.
- In September 2022, Bristol-Myers Squibb Company’s Opdivo has shown efficacy when used as a post-surgery (adjuvant) treatment for patients with melanoma, extending the time before the disease recurrence or patient death in a phase 3 trial. The drug draws parallel to Merck and Co’s rival cancer immunotherapy Keytruda (pembrolizumab), which was approved for adjuvant treatment of melanoma last December.
- In September 2022, Research found that skin cancer patients appear to fare better if received immunotherapy (Cemiplimab) before advancing toward the next stage of surgery. As per the findings, nearly half of the patients could find no cancer cells left at the tumor site following the advanced treatment.
Biomarkers Market- Industry Analysis, Market Size, Share, Trends, Applications
Analysis and Forecast Analysis.
Report Code- HCR 0194
Diagnostics Market- Industry Analysis, Market Size, Share, Trends, Applications
Analysis and Forecast Analysis.
Report Code- HCR 0195
Immunotherapy Market- Industry Analysis, Market Size, Share, Trends,
Applications Analysis and Forecast Analysis.
Report Code- HCR 0197
For more Lifesciences and Healthcare Market reports, please click here